Spots Global Cancer Trial Database for chronic
Every month we try and update this database with for chronic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01901341 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01901302 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Pediatric Longitudinal Cohort Study of Chronic Pancreatitis | NCT03672422 | Pancreatitis, C... Pancreatitis, A... | Blood sample Patient questio... Saliva sample Urine sample | 0 Years - 17 Years | University of Iowa | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00328198 | B-Cell Chronic ... | Alemtuzumab Alemtuzumab | 18 Years - | Sanofi | |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia | NCT01460693 | Myeloid Leukemi... | Imatinib Dasatinib | 18 Years - | Newcastle University | |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | NCT01149668 | Lymphoma Non-Hodgkin's L... Hodgkin Disease Multiple Myelom... Leukemia Lymphocytic | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TKI Discontinuation in CML Patients of China | NCT03251352 | Leukemia Myelogenous Chronic BCR-ABL (Breakp... Positive | 18 Years - | Shenzhen Second People's Hospital | ||
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | NCT04795427 | Leukemia, Chron... | asciminib best available ... | 18 Years - | Novartis | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01901328 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT01578707 | Relapsed or Ref... Small Lymphocyt... | ofatumumab ibrutinib | 18 Years - | Pharmacyclics LLC. | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | NCT00078234 | Chronic Lymphoc... | Oblimersen-ritu... | 18 Years - | Genta Incorporated | |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands | NCT02891551 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | 18 Years - | Celgene | ||
| Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01696643 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes | NCT02281084 | Myelodysplastic... | Oral Azacitidin... Durvalumab | 18 Years - | Celgene | |
| Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01696643 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors | NCT02228382 | Previously Trea... | Bosutinib | 18 Years - | Pfizer | |
| Pediatric Longitudinal Cohort Study of Chronic Pancreatitis | NCT03672422 | Pancreatitis, C... Pancreatitis, A... | Blood sample Patient questio... Saliva sample Urine sample | 0 Years - 17 Years | University of Iowa | |
| The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | NCT01901341 | Opioid-Induced ... | CB-5945 Placebo | 18 Years - 80 Years | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | NCT01559844 | Hepatitis C Hepatocellular ... | Sofosbuvir Ribavirin | 18 Years - | Gilead Sciences | |
| Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia | NCT04043676 | Chronic Myeloid... | Ponatinib | 18 Years - | Fundación Teófilo Hernando, Spain | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | NCT01600053 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University of California, San Diego | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | NCT06427811 | Philadelphia Ch... | Asciminib | 18 Years - | Novartis | |
| Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | NCT01313689 | Leukaemia | Ofatumumab Physicians' Cho... | 18 Years - | Novartis | |
| Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia | NCT00077922 | Leukemia Lymphocytic Chronic | LMB-2 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia | NCT02388048 | Leukemia, Lymph... | Ibrutinib + ofa... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | NCT00021749 | Chronic Lymphoc... CLL | Oblimerson sodi... | 18 Years - | Genta Incorporated | |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | NCT01559844 | Hepatitis C Hepatocellular ... | Sofosbuvir Ribavirin | 18 Years - | Gilead Sciences | |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia | NCT03759184 | Leukemia Lymphocytic Chronic B-Cell | rhIL-15 rhIL-15 Obinutuzumab | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
